RIGL Financials | Income, Balance Sheet & Cash Flow

The financial statements for RIGL (RIGL) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.

See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.

Financial Statements

Related peers

Compare More →
OMER
Omeros Corporation
$12.25
+3.46%
GOSS
Gossamer Bio, Inc.
$0.45
+4.47%
CRVS
Corvus Pharmaceuticals, Inc.
$15.11
-0.92%
FDMT
4D Molecular Therapeutics, Inc.
$9.77
+1.14%
AKBA
Akebia Therapeutics, Inc.
$1.55
-0.64%
R
Ryder System, Inc.
$212.05
-3.54%

Frequently Asked Questions

What are RIGL's latest financial results?

Review RIGL's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.

How has RIGL's revenue and net income changed over time?

Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.

What is RIGL's cash flow situation and liquidity?

Cash flow statements reveal how RIGL generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.

How does RIGL's financial performance compare to industry peers?

Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether RIGL is outperforming or lagging within its sector.

Are RIGL's financial statements showing sustainable profitability?

By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether RIGL's profits are repeatable and supported by strong fundamentals.